Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Farmakologisk långtidsbehandling vid ADHD: Hur skiljer sig substanserna metylfenidat, lisdexamfetamin och atomoxetin?
Linnaeus University, Faculty of Health and Life Sciences, Department of Chemistry and Biomedical Sciences.
2019 (Swedish)Independent thesis Basic level (degree of Bachelor), 10 credits / 15 HE creditsStudent thesisAlternative title
Pharmacological long-term treatment in ADHD : How do the substances methylphenidate, lisdexamfetamine and atomoxetine differ? (English)
Abstract [en]

Attention Deficit Hyperactivity Disorder (ADHD) is a neuropsychiatric disability  characterised by difficulties in paying attention, excessive activity and actions without thinking about the consequenses. Symptoms vary among different individuals in how the disability expresses. Symptoms also vary among different age groups. The cause of ADHD is not yet known, but the main theory seems to be due to disturbed dopaminergic transmisson in the regions of the brain that controlls attention, activity control and impulses. Clinical studies show that there seems to be a connection between the etiology of the disability and genetic- and environmental factors. ADHD can’t be cured but a multimodal treatment has been proven to be effective in symptom reduction. The multimodal treatment consist of psychoeducation, psychotherapy and medical treatment. In Sweden methylphenidate is the first choise of drug and if it is not tolerated well by patients in terms of respons or side effects lisdexamfetamine or atomoxetin is choosen. The mechanism of action for these three substances is not completly known but in general they presume to block the reuptake of dopamine and norepinephrine in the presynaptic neurons. This leads to an enhanced transmission at the dopaminergic neurons that in turn stimulates the executive funtions that seem to be deficient in ADHD patients.

The aim of this literature study is to investigate how the three substances methylphenidate, lisdexamfetamine and atomoxetine differ in therapeutic effects and side effects profile during long-term treatment for ADHD.

Five scientific articles were choosen from the database Pubmed, which analysed the therapeutic effects and side effects of the above choosen drugs during a period of atleast 24 weeks.

Participants in the selected studies had a definite diagnosis of ADHD and the participants included were children, adolescents and also adults. Therapeutic efficiency of selected drugs was measured by using different diagnostic scales such as ADHD-RS-IV, CAARS-Inv:SV, AISRS, CGI-S or CGI-I. Therapeutic efficiency was measured by the total reduction of the mean value in the rating scale from start to end of the study. Safety was measured at each follow up session by evaluating the side effects profile and measurements of vital parameters. These studies show statistically significant symptom reductions for all three selected drugs. The results also show differences in therapeutic effects among different drugs. Participants treated with lisdexamfetamine showed greater symptom reduction and thereby the greatest effect. There may be a difference in therapeutic effect between methylphenidate and atomoxetine but more studies are needed to conclude the results. The adverse effects were similar between lisdexamfetamine and methylphenidate but more serious effects were found during treatment with lisdexamfetamine.

Place, publisher, year, edition, pages
2019. , p. 40
Keywords [sv]
Attention Deficit Hyperactivity Disorder, metylfenidat, lisdexamfetamin, atomoxetin, långtidsbehandling, effektivitet, biverkningar
National Category
Medical and Health Sciences
Identifiers
URN: urn:nbn:se:lnu:diva-84877OAI: oai:DiVA.org:lnu-84877DiVA, id: diva2:1322413
Subject / course
Pharmacy
Educational program
Bachelor of Science Programme in Pharmacy, 180 credits
Supervisors
Examiners
Available from: 2019-06-11 Created: 2019-06-10 Last updated: 2019-06-11Bibliographically approved

Open Access in DiVA

fulltext(748 kB)44 downloads
File information
File name FULLTEXT01.pdfFile size 748 kBChecksum SHA-512
6ccd00e9b9f4c6d0498bbb815740041dcfaa5bc5830ce0a98702f379cb13b8417b8ae472d7cb96558d22dfe69cb707900fc2a2e3cf880bdd5c0e1ed9699b0c6b
Type fulltextMimetype application/pdf

Search in DiVA

By author/editor
Andersson, Lea
By organisation
Department of Chemistry and Biomedical Sciences
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
Total: 44 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

urn-nbn

Altmetric score

urn-nbn
Total: 84 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf